FDA

57 statements across 26 episodes · 18 bullish · 15 bearish · 23 people on the record · first statement Dec 15, 2017 by Jorge Conde · across every show →

Everything said about FDA, oldest first

Dec 15, 2017 positive
Opinion
Conde: The FDA has become an incredible collaborator to industry
“So I think if anything, the FDA has become an incredible collaborator to industry.”
Jorge Conde Dec 15, 2017 ▶ 17:46 Challenges in Healthcare Innovation
Dec 15, 2017 neutral
Insight
Conde: FDA regulatory risk is fundamentally scientific risk
“FDA risk or regulatory risk is really just another way of saying scientific risk, of saying we're going to conduct an experiment, and we are not quite sure what's going to happen.”
Jorge Conde Dec 15, 2017 ▶ 17:00 Challenges in Healthcare Innovation
Apr 30, 2018
Insight
Pande: Reimbursement is a bigger hurdle for diagnostics startups than FDA approval
“Ironically, I think, you know, most people think about the FDA or CLIA being your big, ah, concern. I think reimbursement's probably the first place to start, because I wouldn't want to sort of be designing a test without having the confidence that I'll get re…”
Vijay Pande Apr 30, 2018 ▶ 15:42 Shifting Risk Mindsets, from Tech to Bio
Jan 2, 2019
Assertion Supported
Walden: House subcommittee forced FDA to clarify if iPad is medical device
“We actually did a hearing on my subcommittee to force the FDA, the regulator in this case, to tell us, is an iPad a medical device?”
Greg Walden Jan 2, 2019 ▶ 9:12 a16z Podcast | Innovation and Regulation -- What Happens When Policy Lags Behind Technology?
Jan 2, 2019
Assertion Supported
Kindler: FDA only recently permitted direct electronic clinical data entry
“It was only relatively recently that the FDA Allowed clinical data to be entered directly into computers as opposed to put on paper because there was a reluctance to trust the quality and integrity of that data, which I think we would all agree is kind of sill…”
Jeff Kindler Jan 2, 2019 ▶ 23:13 a16z Podcast | Move Fast But Don't Break Things (When It Comes to Computational Biology)
Jan 2, 2019
Prediction Not checkable as stated
Ullyot: FDA under Trump will speed up trial approvals for healthcare tech
“Presumably will be an FDA that'll be more likely to approve experimentation and special trials to get beneficial drugs and technologies out into the market sooner.”
Ted Ullyot Jan 2, 2019 ▶ 36:52 a16z Podcast | Of Presidents, Policies, and Tech
Jan 2, 2019
Assertion Contradicted
Rando: The FDA will not approve drugs to treat healthy individuals
“There's no way right now that any drug is going to be approved for treatment of healthy people.”
Dr. Thomas Rando Jan 2, 2019 ▶ 18:52 a16z Podcast | The Science Of Extending Life
Jan 2, 2019
Assertion Supported
Pande: FDA approval requires specific disease indications over general longevity
“You probably couldn't even get it through FDA if you didn't have an indication, like staying healthy longer was not an indication.”
Vijay Pande Jan 2, 2019 ▶ 24:48 a16z Podcast | Mindsets for Engineering Biology
Jan 2, 2019 negative
Opinion
Langer: Withdrawing Vioxx from the market in 2005 was wrong
“The second one that I think had a negative effect was the Vioxx situation in 2005, and, you know, there was just a small increase in deaths with this drug, but there were so many lawsuits over it, That people at the FDA would get called on the carpet for appro…”
Bob Langer Jan 2, 2019 ▶ 22:46 a16z Podcast | Mindsets for Engineering Biology
Jan 2, 2019
Assertion Supported
Langer: Artificial hearts still use ladies' girdle material after 50 years
“If you wanted to make an artificial heart, what the clinicians did in 1967 is they said, well, what object in your house has a good flex life like a heart? And they came up with the idea of a lady's girdle. So they looked at what that was made out of, and It's…”
Bob Langer Jan 2, 2019 ▶ 1:11 a16z Podcast | Mindsets for Engineering Biology
Jan 2, 2019 positive
Opinion
Turakhia: FDA's Digital Health Office effectively mitigates regulatory risk
“The regulatory risk thing is being largely addressed by this new Office of Digital Health and the FDA, and they're really doing, seem much more forward thinking about it.”
Mintu Turakhia Jan 2, 2019 ▶ 21:46 a16z Podcast | Putting AI in Medicine, in Practice
Jan 2, 2019 positive
Prediction Held up
Conde: FDA will set an all-time generic drug approval record in 2017
“We'll see more generics approved this year than in any year in history previously.”
Jorge Conde Jan 2, 2019 ▶ 21:23 a16z Podcast | Taking the Pulse on Bio
Jan 17, 2019 positive
Assertion Supported
Novartis launched first FDA-approved prescription app for opioid addiction
“I mean, one example we launched in the U S a digital medicine. I mean, with paratherapeutics, this is the first digital app with an FDA label that's being used for opioid addiction and other psychiatric illnesses. And it is literally an app That has run clinic…”
Vas Narasimhan Jan 17, 2019 ▶ 13:54 a16z Podcast | The Science and Business of Innovative Medicines
Jan 17, 2019 neutral
Assertion Supported
The FDA has approved only about 1,500 new molecular entities in history
“Since the creation of the FDA, there's only been about 1500 new molecular entities ever found.”
Vas Narasimhan Jan 17, 2019 ▶ 58:00 a16z Podcast | The Science and Business of Innovative Medicines
Jan 17, 2019
Assertion Not checkable as stated
Pande: The commercial hurdle for new drugs is reimbursement, not FDA approval
“In a world where things have gone past clinical trials, but really now the new barrier is not getting past the FDA, the new barrier is reimbursement.”
Vijay Pande Jan 17, 2019 ▶ 19:33 a16z Podcast | Dark Data in Healthcare
Feb 26, 2019 neutral
Assertion Supported
Amy Abernethy Named Principal Deputy Commissioner of the FDA
“So first, our special guest is Amy Abernethy, who has been named the new principal deputy commissioner of the FDA, the U.S. Food and Drug Administration, pending ethics clearance.”
Sonal Chokshi Feb 26, 2019 ▶ 0:31 a16z Podcast | Connecting Hearts, Bodies, and Networks to Cure Cancer
Feb 26, 2019 positive
Prediction Not checkable as stated
Abernethy: Core FDA priorities will be evidence generation, personalized medicine, drug design
“When I'm at FDA, I will have a trans-FDA remit, so I will need to spend my time and energy working on the things that the FDA needs me to do, and I'm looking forward to learning more and more about that every day. But I know that I'll at least spend some of my…”
Dr. Amy Abernethy Feb 26, 2019 ▶ 35:00 a16z Podcast | Connecting Hearts, Bodies, and Networks to Cure Cancer
Apr 1, 2019 positive
Insight
Church: Regulators favor breakthrough therapeutic platforms over incremental updates
“To some extent, I think they like new technologies more than they like the old ones. The old ones tend to fail because they're so incremental that they're no longer compared to the placebo, they're compared to whatever they're in increment over, whatever thera…”
George Church Apr 1, 2019 ▶ 13:39 a16z Podcast | What's in the Water at the George Church Lab?
Oct 5, 2019 positive
Assertion Supported
Tran: FDA and CBER introduced accelerated approval guidance for gene therapies
“This past year we've seen FDA and CBER leaders drum up plans to make a big push on assessing new cell and gene therapies, as well as introducing new guidance on accelerated approvals for these new areas of product development.”
Andy Tran Oct 5, 2019 ▶ 9:09 CRISPR 2.0 and the Future of Gene Therapies
Jan 6, 2020 negative
Assertion Supported
Abernethy: Most FDA applications still arrive as static PDF files
“In fact, the way the majority of our applications still come in is through PDFs or sort of essentially large digital representations of what used to come in on trucks.”
Dr. Amy Abernethy Jan 6, 2020 ▶ 4:00 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020
Assertion Supported
Abernethy: FDA maintains an international bacterial genomic database to trace outbreaks
“And one of the things the FDA does in concert with CDC and now really through international database is have, is maintain a database of all the different genomes so that we can also track back and do this more quickly.”
FDA Chief Information Officer Jan 6, 2020 ▶ 40:07 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020 positive
Disclosure
Abernethy: FDA pilots preconditions to allow medical software updates without full review
“Can we come up with, essentially, preconditions for software updates? So that if there are strong quality controls in the way software is developed, well understood product performance as an expect, in terms of the expectation updates, can you now have algorit…”
FDA Chief Information Officer Jan 6, 2020 ▶ 24:34 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020 positive
Disclosure
Abernethy: FDA considers mobile app for consumers to trace produce supply chains
“One of the things we've been contemplating at FDA is, like, ultimately, could you imagine the application on your phone that allows you to scan peaches and understand did the peaches have a full supply chain that we can monitor?”
FDA Chief Information Officer Jan 6, 2020 ▶ 0:00 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020 positive
Assertion Supported
Abernethy: The FDA has approved pharmaceuticals based on Phase 1 data
“We've seen drugs approved based on phase one data.”
FDA Chief Information Officer Jan 6, 2020 ▶ 30:02 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020
Prediction Not checkable as stated
Abernethy: Treatment evaluation will shift toward longitudinal performance tracking over time
“Historically, the way we've often thought about effectiveness is sort of as a fixed book of work, and I think that what you're going to see Over time is we're going to talk more and more about longitudinal performance, and this is a perfect example of that.”
FDA Chief Information Officer Jan 6, 2020 ▶ 43:28 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020 negative
Assertion Supported
Abernethy: HIPAA-de-identified health data remains likely re-identifiable through modern analytics
“Even information that is de-identified from a HIPAA perspective actually still is probably re-identifiable even in our context.”
FDA Chief Information Officer Jan 6, 2020 ▶ 28:13 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020
Assertion Not checkable as stated
Abernethy: FDA can curb addiction by limiting post-surgical opioid prescriptions
“So practically speaking, we can help reduce the number of opioid tablets, for example, a patient has access to after back surgery or knee surgery in order to reduce the chance that this particular person has access and becomes addicted in the first place.”
FDA Chief Information Officer Jan 6, 2020 ▶ 9:59 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020
Assertion Supported
Abernethy: FDA jurisdiction over DIY gene-editing requires commercial intent and labeling
“Practically speaking, if the kit was going to be approved for commercial purposes with claims and labeling, et cetera, that's when it starts to get into the FDA perspective. It gets really murky when we live in this landscape of the internet without claims.”
FDA Chief Information Officer Jan 6, 2020 ▶ 22:23 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020 positive
Assertion Partly supported
Abernethy: The FDA proactively averted over 160 drug shortages in 2018
“In 2018, we had something north of 50 drug shortages, but the little known secret is that we helped to avert over a 160 drug shortages.”
FDA Chief Information Officer Jan 6, 2020 ▶ 13:49 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020 neutral
Assertion Supported
Abernethy: FDA and USDA established a joint regulatory framework for cell-cultured food
“Last year we ultimately developed agreements with USDA so that the parts of the cell cultured food, food activity that's got to do with cell culture, for example, and that, that part of the equation ultimately became The FDA's responsibility, and then as we mo…”
FDA Chief Information Officer Jan 6, 2020 ▶ 37:22 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020 neutral
Assertion Not checkable as stated
Abernethy: Traditional boundaries between clinical trial phases are increasingly blurring
“And a drug or biologic will go through a series of clinical studies, typically phase one through three, although these days those lines are blurring for exactly what drugs, followed then by a new drug application or biologics application of BLA to the FDA.”
FDA Chief Information Officer Jan 6, 2020 ▶ 3:11 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020
Assertion Not checkable as stated
Abernethy: FDA updates its border inspection engine rules manually every year
“And it's true that we update the rules every year, but we do so by hand.”
FDA Chief Information Officer Jan 6, 2020 ▶ 12:22 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020
Assertion Supported
Abernethy: FDA does not directly regulate non-diagnostic healthcare workflow software
“So it may not necessarily be a software product that's acting As a diagnostic or treatment activity, but it's a software product that's intended to support life sciences more globally, whether that's to make clinical trials more efficient, to match patients to…”
FDA Chief Information Officer Jan 6, 2020 ▶ 25:20 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020 neutral
Insight
Pande: FDA faces severe risk asymmetry from unapproved versus harmful drugs
“If there's a great drug that ah, that nobody ever gets, you know, nobody ever knows about it. Let's say there was a cure to cancer, but the FDA didn't approve it. There's no outcry because, ah, no one ever knew about it. But on the other hand, if the FDA let s…”
Vijay Pande Jan 6, 2020 ▶ 5:22 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020
Assertion Contradicted
Abernethy: The FDA regulates approximately 20% of international GDP
“Not only are we responsible for regulating about you know, 20% of international GDP as I mentioned, that sort of was across a broad number of products,”
FDA Chief Information Officer Jan 6, 2020 ▶ 11:04 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020 bullish
Opinion
Abernethy: Emerging biology increases FDA responsibility to objectively assess safety
“And I would argue that in a time of rapidly emerging biology, when we've got more and more scientific innovations and potential products coming to bear, The need to make sure that we have an objective way of assessing safety and effectiveness and providing con…”
FDA Chief Information Officer Jan 6, 2020 ▶ 1:54 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020 positive
Disclosure
Abernethy: FDA is testing machine learning to predict border truck inspections
“And so right now we've got an experiment going on where we're looking at machine learning based prediction of which trucks we should inspect on the border.”
FDA Chief Information Officer Jan 6, 2020 ▶ 12:33 Food, Drugs, and Tech: 100 years of Public Health
Jan 6, 2020 negative
Disclosure
Abernethy: The FDA currently lacks and needs a Chief Privacy Officer
“In my CIO role, I just recently started pushing on the fact that I really think we need a chief privacy role at FDA, which we don't currently have.”
FDA Chief Information Officer Jan 6, 2020 ▶ 26:59 Food, Drugs, and Tech: 100 years of Public Health
Nov 16, 2022 negative
Opinion
Balaji: Media covers drug failures but ignores regulatory delays of effective drugs
“It's because media Only covers it when a drug doesn't work and doesn't cover it when a drug does work, but it's been delayed.”
Balaji Srinivasan Nov 16, 2022 ▶ 1:16:24 The Network State with Balaji Srinivasan
Nov 16, 2022 negative
Assertion Not checkable as stated
Balaji Srinivasan: The FDA caused one million preventable COVID-19 deaths
“And you could have avoided like a million dead. That million dead is on the FDA's head, like, because challenge trials could have been done, you know?”
Balaji Srinivasan Nov 16, 2022 ▶ 1:28:04 The Network State with Balaji Srinivasan
Nov 16, 2022 negative
Opinion
Balaji: FDA prioritizes minimizing its own PR risk over patient choice
“Fundamentally, they're miscalibrated on terms of risk, right? They want to minimize PR risk for themselves, the agency, as opposed to allowing people to take a risk on their own, right?”
Balaji Srinivasan Nov 16, 2022 ▶ 1:16:09 The Network State with Balaji Srinivasan
Nov 16, 2022 negative
Insight
Balaji: FDA delay cost in lives equals delay duration times mortality reduction
“Basically, if you have a drug and it was held up by 10 years, and then once it was approved, it reduced morbidity and mortality by X percentage. That means FDA's delay of 10 years multiplied by that is how many lives it cost. Relative to just taking the risk a…”
Balaji Srinivasan Nov 16, 2022 ▶ 1:16:48 The Network State with Balaji Srinivasan
Nov 16, 2022 bearish
Assertion Not checkable as stated
Balaji Srinivasan: The FDA is holding back tens of trillions of dollars
“Once we can get a zone outside the FDA, once we can exit the FDA, people don't understand how bad the FDA is. Your entire life, it's like tens of trillions of dollars of values being held back by FDA. It's like incalculable how bad they are as an agency.”
Balaji Srinivasan Nov 16, 2022 ▶ 1:18:06 The Network State with Balaji Srinivasan
Dec 12, 2023 positive
Assertion Supported
FDA creates new office and Warp Speed pilot for rare diseases
“The FDA is looking to the skies and taking a page out of the FAA's approach to aviation safety, rigorous yet adaptive. Recently launching its own new office for therapeutic products and piloting Operation Warp Speed for rare disease to create more transparent …”
Jorge Conde Dec 12, 2023 ▶ 2:36 Big Ideas in 2024: Programming Medicine’s Final Frontier with Jorge Conde
Dec 12, 2023 positive
Assertion Supported
FDA approves first CRISPR gene editing therapy for sickle cell anemia
“The breaking news is that the first CRISPR therapy has been approved. This is a therapy for sickle cell anemia and beta thalassemia that was developed by a biopharmaceutical company called Vertex Pharmaceuticals, working with another company called CRISPR Ther…”
Jorge Conde Dec 12, 2023 ▶ 13:58 Big Ideas in 2024: Programming Medicine’s Final Frontier with Jorge Conde
Dec 20, 2023 negative
What-if
Pande: FDA regulations would not have prevented the Thalidomide crisis
“Ironically, nothing that the FDA has done would have helped the phlegmide crisis because you don't test on pregnant women and so on”
Vijay Pande Dec 20, 2023 ▶ 11:23 Tony Robbins on the Future of Health & Longevity
Dec 20, 2023 negative
Insight
Pande: Regulatory delays in drug approvals cause preventable deaths
“If you don't let the drug through, we're actually killing people right now by not getting these advances through, and I think human beings aren't very good at sort of holding that in their head.”
Vijay Pande Dec 20, 2023 ▶ 55:53 Tony Robbins on the Future of Health & Longevity
Dec 20, 2023 negative
Assertion Contradicted
Pande: FDA rejects new drugs that are cheaper but equal in efficacy
“If you had a drug that was as good as the best drug, but cheaper, That still can't get that won't go by the FDA because they actually has to be better than the last drug, even if it's not better scientifically, but it's better in other ways.”
Vijay Pande Dec 20, 2023 ▶ 13:03 Tony Robbins on the Future of Health & Longevity
Mar 13, 2024 neutral
Assertion Supported
Andreessen: AI-designed drugs require standard FDA approval
“It's no more legal to field a new AI design drug without FDA approval than it is a standard design drug.”
Marc Andreessen Mar 13, 2024 ▶ 18:17 America Needs More Techno-Optimism, with Marc Andreessen and Tyler Cowen
May 9, 2024 negative
Opinion
Horowitz: Restricting genetic data access will cost more lives than FDA saves
“I think that this is a interesting, like, weird misapplication of good intentions in a policy way that's probably going to Kill more people than ever get saved by every kind of health, FDA, et cetera, policy that we have”
Ben Horowitz May 9, 2024 ▶ 53:36 Build Your Startup With AI
Dec 18, 2024 positive
Assertion Contradicted
Yoo: Healthcare is uniquely positioned with an existing AI approval framework
“We are the only industry that actually has an existing regulatory framework for approving products, especially in the clinical setting.”
Julie Yoo Dec 18, 2024 ▶ 16:32 AI: The Ultimate Healthcare Hire
Sep 23, 2025
Prediction Open · timeframe Sep 2030
Bhattacharya: FDA will issue updated pregnancy guidelines for acetaminophen use
“There will be, yeah. So that's something that Dr. McCary, the FDA commissioner is working on. And there'll be also you know, changes in, in like how Medicare pays, Medicare, CMS, Medicare, and Medicaid pay for Leucovorin. So it's a cross-agency collaboration f…”
Dr. Jay Bhattacharya Sep 23, 2025 ▶ 4:02 Taking Bold Bets: NIH and the Future of Biomedical Science
Oct 6, 2025 negative
Assertion Not checkable as stated
Wang: Federal personnel costs are a minor part of US budget
“Personnel costs are not a giant aspect of America's budget, and arguably we need a lot more personnel in order to, you know, process drug discoveries and make the FDA much more efficient, Process high-skilled immigrant visas and have a much more functional gov…”
Dan Wang Oct 6, 2025 ▶ 8:21 The Lawyerly Society vs. The Engineering State: Who Owns the Future?
Nov 14, 2025 negative
Assertion Contradicted
Nuzhna: FDA regulation has continuously increased except during the AIDS crisis
“Since the birth of this industry, we only had increasing regulation over time. I think there was like only one time in history of biotech where we made it easier to develop and approve new drugs. And that was during the ACE crisis where AIDS patients were just…”
Lada Nuzhna Nov 14, 2025 ▶ 6:15 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
Nov 14, 2025 neutral
Assertion Supported
Nuzhna: FDA mandatory efficacy testing stems from historical thalidomide crisis
“Since then FDA started to require not just safety, but also efficacy in the approval process.”
Lada Nuzhna Nov 14, 2025 ▶ 7:43 The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation
Mar 9, 2026 bullish
Prediction Not checkable as stated
Huberman: FDA-approved sleepiness drug Sunosi will soon become far more popular
“There's a very interesting drug that I think is going to become far more popular soon, which is already FDA approved called Sunosi, S-U-N-O-S-I, which is approved for excessive daytime sleepiness.”
Dr. Andrew Huberman Mar 9, 2026 ▶ 27:48 Andrew Huberman: Peptides, Sleep Tech, and the End of Obesity
Sep 2, 2026 positive
Prediction Open · timeframe Sep 2029
Bancel: Moderna's Cancer Therapy Will Be Approved via Process BLA
“As you mentioned, CAR-T, CAR-T was also approved in the same way as we believe Intesmiran will be, which is as a process BLA not a product BLA.”
Stéphane Bancel Sep 2, 2026 ▶ 27:47 Inside Moderna’s Biggest mRNA Test Since COVID
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 1,000 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.